Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Cancer Research / Assays zur Validierung von…
JoVE Journal
Cancer Research

A subscription to JoVE is required to view this content.

JoVE Journal Cancer Research
Assays zur Validierung von Histon-Acetyltransferase-Inhibitoren
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
Journal (Cancer Research)
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
Detection of Lung Tumor Progression in Mice by Ultrasound Imaging
Journal (Cancer Research)
Detection of Lung Tumor Progression in Mice by Ultrasound Imaging
 
Click here for the English version

Assays zur Validierung von Histon-Acetyltransferase-Inhibitoren

Article DOI: 10.3791/61289-v • 09:11 min • August 6th, 2020
August 6th, 2020 •
1, 1
1Department of Anatomy and Cell Biology, and UF Health Cancer Center, University of Florida College of Medicine

Chapters

Summary
Automatic Translation

Please note that all translations are automatically generated.

Click here for the English version.

Inhibitoren von Histonacetyltransferasen (HATs, auch bekannt als Lysin-Acetyltransferasen), wie CBP/p300, sind potenzielle Therapeutika zur Behandlung von Krebs. Es sind jedoch strenge Methoden zur Validierung dieser Inhibitoren erforderlich. Drei In-vitro-Methoden zur Validierung umfassen HAT-Assays mit rekombinanten Acetyltransferasen, Immunoblotting für Histonacetylierung in der Zellkultur und ChIP-qPCR.

Tags

Krebsforschung Ausgabe 162 Lysin-Acetyltransferasen KATs CBP/p300 Histon-Acetyltransferase-Inhibitoren Screening-Methoden Histonacetylierung Epigenetik Krebs Genregulation
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter